1. Maestro, Sheila, Weber, Nicholas D, Zabaleta, Nerea, Aldabe, Rafael, Gonzalez-Aseguinolaza, Gloria. 2021. Novel vectors and approaches for gene therapy in liver diseases. In JHEP reports : innovation in hepatology, 3, 100300. doi:10.1016/j.jhepr.2021.100300. https://pubmed.ncbi.nlm.nih.gov/34159305/
2. Han, Bing, He, Yiwen, Zhu, Min, Yi, Honggang, Tang, Shaowen. 2024. Association of Gene Polymorphisms and Serum Levels of ALAS1 with the Risk of Anti-Tuberculosis Drug-Induced Liver Injury. In Journal of clinical pharmacology, 65, 197-205. doi:10.1002/jcph.6137. https://pubmed.ncbi.nlm.nih.gov/39297668/
3. Ju, Yunfeng, Mizutani, Tetsuya, Imamichi, Yoshitaka, Kangawa, Kenji, Miyamoto, Kaoru. 2012. Nuclear receptor 5A (NR5A) family regulates 5-aminolevulinic acid synthase 1 (ALAS1) gene expression in steroidogenic cells. In Endocrinology, 153, 5522-34. doi:10.1210/en.2012-1334. https://pubmed.ncbi.nlm.nih.gov/23024262/
4. Oliveri, Leda M, Davio, Carlos, Batlle, Alcira M del C, Gerez, Esther N. . ALAS1 gene expression is down-regulated by Akt-mediated phosphorylation and nuclear exclusion of FOXO1 by vanadate in diabetic mice. In The Biochemical journal, 442, 303-10. doi:10.1042/BJ20111005. https://pubmed.ncbi.nlm.nih.gov/22070747/
5. Zhao, Yalei, Zhang, Xiaoyun, Liu, Yabin, Han, Mei, Li, Binghui. . Inhibition of ALAS1 activity exerts anti-tumour effects on colorectal cancer in vitro. In Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association, 26, 144-152. doi:10.4103/sjg.SJG_477_19. https://pubmed.ncbi.nlm.nih.gov/32270771/
智鼠故事 
